What’s the Link Between Erectile Dysfunction & Prostate Cancer?

Erectile dysfunction and prostate cancer are linked in several distinct ways, though not in the direction most people assume. Having ED does not meaningfully raise your risk of developing prostate cancer, but the two conditions share overlapping risk factors like aging and low testosterone. The more consequential connection runs in the other direction: prostate cancer treatment, whether surgery, radiation, or hormone therapy, frequently causes or worsens ED. Even the biopsy used to diagnose prostate cancer can temporarily dampen erections. Understanding each thread of this relationship matters because it shapes treatment choices, recovery expectations, and quality of life for years after a cancer diagnosis.

Do They Share Risk Factors?

ED and prostate cancer both become more common with age, and both occur against a backdrop of hormonal and vascular changes. Researchers have explored whether ED itself signals a higher chance of prostate cancer, partly because some risk factors overlap between the two conditions.¹ The evidence for a direct causal link is weak. Large observational studies have not consistently shown that men with ED are diagnosed with prostate cancer at higher rates, once you account for the fact that men with ED visit urologists more often and are therefore screened more frequently.

Low testosterone is one area where the biology genuinely intersects. Men with lower serum testosterone levels are more likely to present with higher-grade prostate tumors when cancer is detected. One study of 155 men with prostate cancer found that a third had partial androgen deficiency, and their average Gleason score (a measure of tumor aggressiveness) was substantially higher than in men with normal testosterone levels.² A separate study confirmed that low testosterone was an independent predictor of high-grade disease after adjusting for age, body mass, and race, and found the association was even stronger among Black men.³ Since low testosterone is also a well-known contributor to ED, the same hormonal environment can set the stage for both problems without one causing the other.

Can a Prostate Biopsy Itself Cause ED?

This is a common worry, and the answer is yes, but temporarily. A systematic review and meta-analysis found that erection scores dropped by a clinically meaningful margin about one month after biopsy, then returned to baseline by three months.⁴ A second meta-analysis reached essentially the same conclusion, reporting a significant dip at one month that resolved by three to six months afterward.⁵ The mechanism is likely a combination of local inflammation, anxiety about results, and temporary nerve irritation rather than lasting structural damage.

For men on active surveillance, who undergo repeated biopsies over years to monitor a low-risk cancer without treating it, the picture is reassuring. A longitudinal study tracking men for up to five years on active surveillance found that erectile function declined by roughly one point per year on a 30-point scale, a rate indistinguishable from normal aging. The researchers concluded that surveillance-related biopsies do not appear to have a large independent impact on erections.⁶ That said, the proportion of these men using ED medications rose from about 5% at baseline to 27% by year five, which likely reflects aging and the psychological weight of living with a cancer diagnosis rather than the biopsies themselves.

How Radical Prostatectomy Affects Erections

Surgery to remove the prostate is the most common cause of treatment-related ED, and its impact is dramatic. Erections depend on the cavernous nerves, two bundles that run along either side of the prostate. Removing the gland can stretch, bruise, or sever those nerves. Even when a surgeon deliberately preserves them using a nerve-sparing technique, the nerves sustain some trauma, and recovery is slow. Natural return of erections can take 18 to 24 months.⁷

The difference between nerve-sparing and non-nerve-sparing surgery is significant. A systematic review and meta-analysis found that nerve-sparing reduced the relative risk of ED by about 23% at three months and by about 47% at 12 months compared to non-nerve-sparing approaches.⁸ When bilateral sparing (preserving nerves on both sides) was attempted, about 87% of previously potent men regained potency by one year. That figure dropped to roughly 53% when only partial nerve preservation was possible due to the location or extent of the tumor.⁹

In higher-risk cancers, where the tumor sits close to or has grown into the nerve bundles, surgeons face a trade-off. Sparing nerves improves sexual outcomes, but it must not compromise cancer removal. A propensity-matched analysis of high-risk patients found that only about 3% of men who underwent non-nerve-sparing surgery achieved unaided erections by two years, compared with modestly better odds when one or both bundles were preserved.¹⁰ Published potency rates after nerve-sparing range widely, from 40% to 86%, depending on the study population, surgical technique, and how “potency” is defined.¹¹

How Radiation Therapy Affects Erections

Radiation treats prostate cancer differently from surgery, but it also damages erectile tissue, just on a longer timeline. Rather than directly injuring nerves, radiation causes progressive damage to the blood vessels that supply erections, particularly the internal pudendal arteries. Studies have documented structural arterial changes and disruptions in the smooth-muscle tone that allows blood to fill the penis.¹² The result is a vascular form of ED that tends to develop gradually over months to years after treatment, rather than appearing immediately.

Patients sometimes hear that one type of radiation is gentler than another. Brachytherapy, which places radioactive seeds directly into the prostate, does appear to have a short-term advantage over external beam radiation in terms of sexual function scores. But a meta-analysis that pooled results across studies found this difference was statistically significant only in the immediate post-treatment period and faded by three months, remaining undetectable at one and two years.¹³ When brachytherapy was compared head-to-head with both external beam radiation and surgery, brachytherapy patients did report better erectile function scores overall after adjusting for age and baseline function, with an advantage of several points on a standard questionnaire compared to surgery and a smaller edge over external beam radiation.¹⁴ The takeaway: radiation generally preserves erections better than surgery in the short term, but the gap narrows over time, and no form of radiation therapy leaves erectile function untouched.

Hormonal Therapy and the Loss of Libido

Androgen deprivation therapy, or ADT, works by suppressing testosterone to starve the cancer of the hormone it uses to grow. The sexual side effects are sweeping and predictable. By reducing testosterone to near-castrate levels, ADT diminishes libido, reduces the frequency and quality of erections, and can alter orgasmic sensation. Unlike surgical or radiation-related ED, where the problem is primarily mechanical (nerve or blood vessel damage), ADT attacks desire itself. Many men on ADT report that they simply stop thinking about sex, which makes the erectile dimension feel secondary.¹⁵

ADT is often combined with radiation or used after surgery in high-risk patients, which compounds the problem. A man who undergoes radiation and ADT simultaneously is dealing with vascular damage from the radiation plus hormonal suppression from ADT. Some of the sexual effects of ADT reverse once treatment stops, but recovery depends on the duration of therapy. Short courses of a few months tend to produce reversible effects, while years of ADT can lead to more lasting changes in sexual function and body composition.

Focal Therapy as a Less Damaging Option

For men with localized, low-to-intermediate-risk prostate cancer, focal therapies aim to destroy the tumor while leaving the rest of the gland and surrounding nerves intact. Techniques include high-intensity focused ultrasound (HIFU), cryotherapy, and laser ablation. The sexual function results so far have been encouraging. A pilot randomized trial comparing HIFU with radical prostatectomy in 82 men found significantly better sexual function outcomes in the HIFU group.¹⁶

A systematic review covering multiple focal treatment types reported generally good erectile recovery at one year across studies.¹⁷ The caveat is that most of this evidence comes from small, heterogeneous studies without long-term follow-up. Focal therapy is a newer approach, and oncologists are still working to ensure that the cancer control is equivalent to more established treatments. If you’re a candidate for focal therapy based on your tumor’s characteristics, it’s worth a detailed conversation with your urologist about the trade-off between the lighter side-effect profile and the somewhat thinner evidence base on long-term cancer outcomes.

Penile Rehabilitation After Treatment

The idea behind penile rehabilitation is simple: if you don’t use the erectile tissue during the long recovery window after surgery, structural changes in the penis (loss of smooth muscle, buildup of scar tissue, reduced oxygen supply) can make recovery harder or impossible. Starting some form of erection-promoting treatment early, typically ED medications, injections, or vacuum devices, aims to keep the tissue healthy until the nerves recover on their own.

The concept has strong support from laboratory studies showing that early intervention prevents tissue damage in animal models, and one early randomized trial found that men who received penile injections soon after nerve-sparing surgery recovered spontaneous erections at far higher rates than those who did not, with about two-thirds of the injection group regaining adequate erections compared to one-fifth of the control group.¹⁸ However, larger and more rigorous trials since then have produced mixed results, and researchers acknowledge that solid long-term evidence demonstrating a definitive benefit of rehabilitation over no intervention is still lacking.¹⁹

One persistent challenge with penile injection programs is adherence. Injecting medication into the penis before sex is understandably unappealing, and dropout rates are high. A study of post-prostatectomy patients using injection-based rehabilitation found that patient motivation and partner support were critical to sticking with the program, and that counseling the couple together helped reduce dropout.²⁰ Among men who did continue with injections past the first year, about three-quarters still felt the treatment improved their erections at two years, though satisfaction declined somewhat over time.²¹

When Medications and Rehabilitation Are Not Enough

For men whose ED does not respond to oral medications, injections, or vacuum devices, a penile prosthesis (inflatable implant) is often the last-resort option and, somewhat counterintuitively, one of the most satisfying. A study evaluating inflatable implants reported that erectile function scores more than doubled after surgery, and the vast majority of recipients rated their satisfaction as “very satisfied” or higher at one year.²²

Despite high satisfaction rates, only a small fraction of prostate cancer patients who develop ED end up receiving an implant. Among more than 13,800 prostate cancer patients with ED in one large database study, only about 2.5% received an inflatable prosthesis. Men who had undergone prostatectomy were significantly more likely to get one compared to men treated with radiation, possibly because surgical patients tend to have more severe ED and reach the limits of other treatments sooner.²³

The Psychological Side of the Equation

Prostate cancer creates a particular psychological trap around sexual function. Depression and anxiety are common at every stage, from the stress of waiting for biopsy results through the confusion of choosing among treatment options. ED compounds these feelings, and the emotional fallout from ED in turn makes the physical problem harder to address.²⁰ Many couples find that the strain is not just about erections but about a broader change in intimacy, communication, and self-image.

Structured sexual rehabilitation programs that include the partner show some promise, though the evidence is still evolving. One randomized trial of a couples-based intervention found improvements in sexual function and distress at three months, but gains faded by six months. The lasting benefit was behavioral: men who participated were significantly more likely to start using ED treatments, which suggests the program lowered barriers to seeking help.²⁴ A larger randomized trial tested a more comprehensive sexual recovery program and found no difference in overall sexual satisfaction at six months, though participants reported engaging in more sexual activity, both penetrative and nonpenetrative, at three months.²⁵ The emerging picture is that counseling helps couples adapt, but it is not a substitute for addressing the physical drivers of ED.

Predicting Who Will Recover

Not every man who has prostate cancer treatment ends up with permanent ED, and knowing the odds in advance can shape both treatment decisions and expectations. Researchers have developed predictive models, or nomograms, that estimate a man’s chance of recovering erections based on factors like his age, baseline erectile function before treatment, the type and extent of surgery, and the presence of other health conditions. One set of validated nomograms achieved accuracy scores (concordance indexes) above 0.76, and a late postoperative model that incorporated early recovery data was especially accurate.²⁶ More recently, machine learning models have been applied to the same question. An artificial neural network model predicting potency after robotic prostatectomy achieved a reasonable accuracy score, with age, existing health problems, and preoperative erectile function emerging as the strongest predictors.²⁷

The practical lesson from these models is that baseline erectile function matters enormously. A man who has strong, reliable erections before treatment is far more likely to recover them afterward, regardless of the technique used. Conversely, a man who already has mild ED going into treatment should expect a longer and less certain path back. This makes the pretreatment assessment of erections an important but often underemphasized part of the conversation with your surgeon or radiation oncologist.

Experimental Approaches on the Horizon

Low-intensity shockwave therapy, which delivers focused energy pulses to penile tissue to stimulate blood vessel growth, has shown promising results for garden-variety vascular ED. Whether it works for post-prostatectomy ED is a different question, because the underlying problem is nerve injury rather than purely vascular disease. A critical review found that nearly all clinical trials of shockwave therapy excluded men with post-surgical ED, leaving the evidence base thin for this specific group.²⁸

Animal research has been more adventurous. In a rat model of post-prostatectomy ED, combining stem cells applied to the injured nerves with shockwave therapy aimed at the erectile tissue produced better results than either treatment alone. The combination improved blood flow, preserved smooth muscle, and increased the molecular signals involved in erection.²⁹ These findings are intriguing but years away from human application. For now, the available treatments remain medications, injections, vacuum devices, and implants, and the most meaningful variable remains how much nerve and vascular damage the cancer treatment inflicts in the first place.